BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BMY - US1101221083 - Common Stock
39.635 EUR
+1.23 (+3.22%)
Taking everything into account, 1BMY scores 6 out of 10 in our fundamental rating. 1BMY was compared to 53 industry peers in the Pharmaceuticals industry. 1BMY has only an average score on both its financial health and profitability. 1BMY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. 1BMY also has an excellent dividend rating. With these ratings, 1BMY could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
In the past year 1BMY was profitable.
1BMY had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1BMY reported negative net income in multiple years.
In the past 5 years 1BMY always reported a positive cash flow from operatings.
1.2 Ratios
1BMY has a Return On Assets (6.23%) which is comparable to the rest of the industry.
1BMY has a Return On Equity of 32.55%. This is in the better half of the industry: 1BMY outperforms 80.00% of its industry peers.
The Return On Invested Capital of 1BMY (17.49%) is better than 81.82% of its industry peers.
1BMY had an Average Return On Invested Capital over the past 3 years of 11.67%. This is below the industry average of 13.94%.
The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(17.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 17.49% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
1BMY has a Profit Margin (12.57%) which is comparable to the rest of the industry.
With an excellent Operating Margin value of 33.51%, 1BMY belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
1BMY's Operating Margin has declined in the last couple of years.
The Gross Margin of 1BMY (73.15%) is comparable to the rest of the industry.
1BMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
1BMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
1BMY has less shares outstanding than it did 1 year ago.
1BMY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for 1BMY is higher compared to a year ago.
2.2 Solvency
1BMY has an Altman-Z score of 2.10. This is not the best score and indicates that 1BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
1BMY's Altman-Z score of 2.10 is on the low side compared to the rest of the industry. 1BMY is outperformed by 60.00% of its industry peers.
1BMY has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as 1BMY would need 3.20 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.20, 1BMY is doing good in the industry, outperforming 61.82% of the companies in the same industry.
1BMY has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.41, 1BMY is doing worse than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.1 |
ROIC/WACC2.11
WACC8.3%
2.3 Liquidity
1BMY has a Current Ratio of 1.27. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
1BMY has a Current ratio of 1.27. This is in the lower half of the industry: 1BMY underperforms 65.45% of its industry peers.
1BMY has a Quick Ratio of 1.17. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of 1BMY (1.17) is better than 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 460.68% over the past year.
Measured over the past years, 1BMY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
1BMY shows a small growth in Revenue. In the last year, the Revenue has grown by 1.26%.
Measured over the past years, 1BMY shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
1BMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.26% yearly.
1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.97% yearly.
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.04 indicates a rather cheap valuation of 1BMY.
Based on the Price/Earnings ratio, 1BMY is valued cheaply inside the industry as 94.55% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of 1BMY to the average of the S&P500 Index (26.55), we can say 1BMY is valued rather cheaply.
1BMY is valuated cheaply with a Price/Forward Earnings ratio of 7.57.
1BMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BMY is cheaper than 90.91% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 1BMY to the average of the S&P500 Index (23.78), we can say 1BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.04 | ||
| Fwd PE | 7.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1BMY is valued cheaply inside the industry as 92.73% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 1BMY is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.14 | ||
| EV/EBITDA | 5.97 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMY's earnings are expected to grow with 73.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.22%
EPS Next 3Y73.98%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.77%, 1BMY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.83, 1BMY pays a better dividend. On top of this 1BMY pays more dividend than 90.91% of the companies listed in the same industry.
1BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
5.2 History
On average, the dividend of 1BMY grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1BMY pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
The dividend of 1BMY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
BIT:1BMY (11/20/2025, 7:00:00 PM)
39.635
+1.23 (+3.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap80.69B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price Target45.28 (14.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)2.04%
PT rev (3m)-2%
EPS NQ rev (1m)5.31%
EPS NQ rev (3m)4.49%
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.41%
Revenue NQ rev (1m)1.98%
Revenue NQ rev (3m)2.19%
Revenue NY rev (1m)1.32%
Revenue NY rev (3m)1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.04 | ||
| Fwd PE | 7.57 | ||
| P/S | 1.96 | ||
| P/FCF | 6.14 | ||
| P/OCF | 5.65 | ||
| P/B | 5.06 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.97 |
EPS(TTM)5.63
EY14.2%
EPS(NY)5.23
Fwd EY13.2%
FCF(TTM)6.45
FCFY16.29%
OCF(TTM)7.01
OCFY17.69%
SpS20.26
BVpS7.83
TBVpS-9.98
PEG (NY)0.01
PEG (5Y)N/A
Graham Number31.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 17.49% | ||
| ROICexc | 22.99% | ||
| ROICexgc | 117.18% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.1 |
F-Score6
WACC8.3%
ROIC/WACC2.11
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year262.1%
EBIT Next 3Y50.55%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ
Can you provide the ChartMill fundamental rating for BRISTOL-MYERS SQUIBB CO?
ChartMill assigns a fundamental rating of 6 / 10 to 1BMY.MI.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (1BMY.MI) stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (1BMY.MI). This can be considered as Undervalued.
Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a profitability rating of 5 / 10.
What is the financial health of BRISTOL-MYERS SQUIBB CO (1BMY.MI) stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 5 / 10.
How sustainable is the dividend of BRISTOL-MYERS SQUIBB CO (1BMY.MI) stock?
The dividend rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 8 / 10 and the dividend payout ratio is 82.81%.